Analyzing Vir Biotechnology (NASDAQ:VIR) and Tango Therapeutics (NASDAQ:TNGX)

Vir Biotechnology (NASDAQ:VIR) and Tango Therapeutics (NASDAQ:TNGX) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, earnings, profitability, institutional ownership, valuation and risk.

Valuation and Earnings

This table compares Vir Biotechnology and Tango Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vir Biotechnology	$68.56 million	25.97	-$437.99 million	($1.86)	-5.66
Tango Therapeutics	$62.38 million	63.11	-$101.59 million	($0.85)	-27.47

Tango Therapeutics has lower revenue, but higher earnings than Vir Biotechnology. Tango Therapeutics is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

65.3% of Vir Biotechnology shares are held by institutional investors. Comparatively, 79.0% of Tango Therapeutics shares are held by institutional investors. 2.9% of Vir Biotechnology shares are held by insiders. Comparatively, 6.5% of Tango Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Vir Biotechnology and Tango Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vir Biotechnology	1	0	6	1	2.88
Tango Therapeutics	1	2	13	0	2.75

Vir Biotechnology presently has a consensus target price of $21.57, suggesting a potential upside of 105.05%. Tango Therapeutics has a consensus target price of $43.46, suggesting a potential upside of 86.13%. Given Vir Biotechnology’s stronger consensus rating and higher probable upside, equities analysts clearly believe Vir Biotechnology is more favorable than Tango Therapeutics.

Risk & Volatility

Vir Biotechnology has a beta of 1.63, meaning that its stock price is 63% more volatile than the S&P 500. Comparatively, Tango Therapeutics has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500.

Profitability

This table compares Vir Biotechnology and Tango Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vir Biotechnology	-638.88%	-29.99%	-23.62%
Tango Therapeutics	N/A	-25.75%	-23.36%

Summary

Tango Therapeutics beats Vir Biotechnology on 9 of the 15 factors compared between the two stocks.

About Vir Biotechnology

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

About Tango Therapeutics

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.